We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-2.85%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.08B
AUM Growth
-$190M
Cap. Flow
-$78.5M
Cap. Flow %
-7.25%
Top 10 Hldgs %
76.04%
Holding
46
New
4
Increased
2
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$14.6M
2
CELC icon
Celcuity
CELC
+$10.2M
3
ABEO icon
Abeona Therapeutics
ABEO
+$9.4M
4
CRBP icon
Corbus Pharmaceuticals
CRBP
+$7.02M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$3.76M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$46.7M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$20.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$16.4M
4
GTH
Genetron Holdings Limited ADS
GTH
+$10.9M
5
SVRA icon
Savara
SVRA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
26
DELISTED
Tourmaline Bio
TRML
$7.61M 0.7%
591,882
– –
CRBP icon
27
Corbus Pharmaceuticals
CRBP
$166M
$7.55M 0.7%
+166,794
New +$7.02M
IOBT
28
DELISTED
IO Biotech
IOBT
$7.22M 0.67%
6,173,439
– –
TIL icon
29
Instil Bio
TIL
$48.3M
$6.42M 0.59%
624,339
+1
+0% +$11
ENGN icon
30
enGene Therapeutics
ENGN
$120M
$6.4M 0.59%
678,705
– –
VSTM icon
31
Verastem
VSTM
$510M
$4.58M 0.42%
1,538,461
– –
CMPX icon
32
Compass Therapeutics
CMPX
$344M
$3.56M 0.33%
3,556,023
– –
ALLK
33
DELISTED
Allakos
ALLK
$2.99M 0.28%
2,988,000
– –
BOLT icon
34
Bolt Biotherapeutics
BOLT
$7.67M
$2.64M 0.24%
176,065
– –
UNCY icon
35
Unicycive Therapeutics
UNCY
$137M
$1.74M 0.16%
347,015
– –
ALGS icon
36
Aligos Therapeutics
ALGS
$26.2M
$1.24M 0.11%
141,881
– –
CDXS icon
37
Codexis
CDXS
$151M
$1.2M 0.11%
388,144
– –
DBVT
38
DBV Technologies
DBVT
$799M
$1.08M 0.1%
270,887
-1
-0% -$6
ADVM
39
DELISTED
Adverum Biotechnologies
ADVM
$833K 0.08%
833,333
-666,667
-44% -$6.2M
WHWK
40
Whitehawk Therapeutics
WHWK
$190M
$744K 0.07%
509,572
– –
QTTB icon
41
Q32 Bio
QTTB
$466M
$369K 0.03%
20,559
-349,509
-94% -$8.36M
DTIL icon
42
Precision BioSciences
DTIL
$180M
$45.5K ﹤0.01%
4,675
– –
CRNX icon
43
Crinetics Pharmaceuticals
CRNX
$8.84B
– –
-350,000
Closed -$16.4M
SVRA icon
44
Savara
SVRA
$1.12B
– –
-2,088,323
Closed -$10.4M
ALPN
45
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-520,505
Closed -$20.8M
GTH
46
DELISTED
Genetron Holdings Limited ADS
GTH
– –
-2,708,056
Closed -$10.9M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Vivo Capital held 46 positions worth $1.08B, down 15% from $1.27B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Vivo Capital withdrew a net $78.5M in Q2 2024, closing 4 positions and reducing 6 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Erasca worth $15.9M.

  • Vivo Capital's largest Q2 2024 buy was Erasca: 6,756,756 shares worth $15.9M.
  • Vivo Capital added most to Oric Pharmaceuticals in Q2 2024, an estimated $3.76M increase.
  • Vivo Capital's biggest Q2 2024 reduction was Soleno Therapeutics, cutting an estimated $46.7M.
  • Vivo Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $20.8M.
  • Vivo Capital's ten largest holdings make up 76% of its $1.08B portfolio in Q2 2024.
  • Vivo Capital opened 4 new positions and closed 4 in Q2 2024.
  • Vivo Capital's portfolio value fell 15% quarter-over-quarter to $1.08B.

Based on Vivo Capital's 13F filing for Q2 2024, filed 14 Aug 2024.